Krystal Biotech, Inc. Q3 FY2026 earnings call

• Commercial Growth & Access:

  • Global cumulative Visevic revenue since launch has reached approximately $1.1 billion.
  • In the U.S., more than 760 reimbursement approvals have been secured, and approximately 80% of patients now self-administer treatment at home.
  • International expansion is accelerating; pricing negotiations are complete in Germany, Italy, and Japan. Launches or significant progress are underway in France (home administration milestone), Spain (pricing discussions ongoing), and Italy (launch expected early 2027).
  • The company is broadening its treatment network beyond expert centers to reach more patients globally.

• Pipeline Progress:

  • Gorlin Syndrome (KB113): Initial pilot study results showed profound anti-tumor responses, with over 80% of lesions regressing and histological confirmation of complete clearance in injected tumors. Evidence suggests a systemic abscopal effect. Engagement with the FDA regarding next steps is underway.
  • Haley-Haley Disease (KB111): Enrollment of five patients in the repeat-dose study is complete. Data update expected before year-end, followed by FDA meetings.
  • Ocular DEB (KBA03): Three additional patients enrolled in the registrational ILI study. Top-line results expected shortly after the last patient visit in February 2027.
  • NK Patients (NKB 801): Enrollment progressing slower than anticipated due to stringent criteria and competition from Oxovate. Expanding site network to include EU regions to improve enrollment rates. Top-line results expected in 2027.
  • Cystic Fibrosis (KB407): Dosing three patients in repeat-dose study; interim results expected in H1 2027. Selected for FDA’s Complex Innovative Design Meeting Program.
  • Oncology (KB707): Dose optimization completed for NSCLC program; expect to enroll 70 patients by mid-2027.

• Financial Strength & Capital Allocation:

  • Ended September with $1.2 billion in cash and investments.
  • Board authorized a $400 million share repurchase program over the next two years, reflecting confidence in long-term prospects and financial flexibility.
  • Gross margin was 94%, down slightly from 96% in the prior year due to international sales mix and lower-cost R&D batch sales in the previous period.
  • Operating expenses decreased, aided by insurance proceeds reimbursing legal costs.

• Visevic (Global): Revenue of $127.3 million, a 30% increase year-over-year. This includes U.S. net revenue of $95.3 million and International revenue of $32.0 million.
• U.S. Commercial: Generated $95.3 million in net revenue, driven by demand for VigeVac (Visevic) and an expanding prescriber base with over 80 new additions this quarter.
• International Commercial: Generated $32.0 million in revenue, supported by pricing conclusions in Germany, Italy, and Japan, and home administration milestones in France.

• Full Year Non-GAAP R&D and SG&A Guidance Revised Downward:
  • Revised range: $155 million to $165 million.
  • Previous guidance: $175 million to $195 million.
  • Reduction attributed to receipt of insurance proceeds for legal costs and lower marketing/legal fees compared to prior periods.
• Clinical Readouts:
  • Management expects to share data updates for KB111 (Haley-Haley) before year-end.
  • KBA03 (Ocular DEB) top-line results expected shortly after February 2027.
  • NKB 801 (NK) and KB407 (CF) top-line results expected in 2027.

• Clinical Trial Delays and Enrollment Challenges:
  • Slower-than-anticipated enrollment in the NK (NKB 801) program due to narrowly defined eligibility criteria, competition from existing therapies (Oxovate), and administrative delays with academic sites.
  • Patient withdrawals in the Ocular DEB (KBA03) trial due to non-compliance with weekly dosing schedules and logistical issues.
• Regulatory and Pricing Uncertainty:
  • International revenue accruals may remain volatile until pricing and reimbursement negotiations conclude in key markets like Spain and the UK.
  • Dependence on successful FDA interactions for novel endpoints and development pathways, particularly for Gorlin Syndrome and CF programs.
• Operational Execution:
  • Risk that clinical readouts continue to take longer than initially expected, impacting pipeline timeline visibility.

Q: Analyst asked about the rationale for enrolling additional patients in the CF KB407 trial and how Japan adoption might accelerate as prescription restrictions lift. / A: Suma Krishnan clarified that the additional enrollment aims to assess safety and tolerability of repeat dosing rather than dose testing, noting some delays due to patient illness. Krish Krishnan added that Japan's prescription frequency is set to reduce from twice to once monthly in late 2026, which should incentivize faster adoption given commute distances.

Q: Analyst inquired about capital allocation strategy, questioning if increased R&D spend could accelerate delayed trials like NK and CF instead of initiating share buybacks. / A: CEO Krish Krishnan stated the buyback authorization reflects high comfort in revenue visibility and pipeline funding needs. He emphasized that while they are open to increasing investment if it immediately translates to faster enrollment or site openings, the current balance sheet ($1.2B cash + $400M buyback authority) provides sufficient resources to pursue both commercial expansion and pipeline acceleration without compromising shareholder returns.

Q: Analyst sought details on NK trial enrollment drivers, specifically regarding exclusion criteria causing screen failures and plans to expand sites beyond the US. / A: Suma Krishnan explained that stringent inclusion criteria require persistent lesions to ensure robust placebo-controlled differentiation, leading to screen failures among milder cases. To address slow US enrollment due to competition from Oxovate, the company is aggressively activating additional sites in the US and expanding into EU and Eastern European regions to access larger patient pools.

Q: Analyst asked about the Gorlin Syndrome (KB113) program, specifically regarding FDA discussions and feasibility of pivotal trial size given the observed abscopal effect. / A: Suma Krishnan highlighted remarkable consistency in responses across all three pilot patients, with histological confirmation of complete tumor clearance. She noted that because Gorlin lesions do not heal spontaneously, the observed effects are clearly drug-driven. Given the strong response rates, she indicated a pivotal trial would likely be feasible with fewer than 100 patients, avoiding the need for a large-scale study.

Q: Analyst questioned the timing of Ocular DEB vs. NK readouts and requested clarification on ITT population handling for withdrawn patients in the Ocular DEB trial. / A: CEO Krish Krishnan confirmed that Ocular DEB data will be reported ahead of NK. Suma Krishnan clarified that the two withdrawn patients in the Ocular DEB trial will be included in the Intent-to-Treat (ITT) efficacy population. The statistical analysis plan incorporates sensitivity analyses and natural history data to account for potential carryover effects from the crossover design, ensuring a robust assessment of therapeutic efficacy.